Cargando…
Clinical Outcomes and Plasma Concentrations of Baloxavir Marboxil and Favipiravir in COVID-19 Patients: An Exploratory Randomized, Controlled Trial
Background: Effective antiviral drugs for COVID-19 are still lacking. This study aims to evaluate the clinical outcomes and plasma concentrations of baloxavir acid and favipiravir in COVID-19 patients. Methods: Favipiravir and baloxavir acid were evaluated for their antiviral activity against SARS-C...
Autores principales: | Lou, Yan, Liu, Lin, Yao, Hangping, Hu, Xingjiang, Su, Junwei, Xu, Kaijin, Luo, Rui, Yang, Xi, He, Lingjuan, Lu, Xiaoyang, Zhao, Qingwei, Liang, Tingbo, Qiu, Yunqing |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier B.V.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7585719/ https://www.ncbi.nlm.nih.gov/pubmed/33115675 http://dx.doi.org/10.1016/j.ejps.2020.105631 |
Ejemplares similares
-
Efficacy of baloxavir marboxil on household transmission of influenza infection
por: Umemura, Takumi, et al.
Publicado: (2020) -
Baloxavir Marboxil: An Original New Drug against Influenza
por: Dufrasne, François
Publicado: (2021) -
Characterization of influenza virus variants induced by treatment with the endonuclease inhibitor baloxavir marboxil
por: Omoto, Shinya, et al.
Publicado: (2018) -
Susceptibility of Influenza Viruses to the Novel Cap-Dependent Endonuclease Inhibitor Baloxavir Marboxil
por: Takashita, Emi, et al.
Publicado: (2018) -
The antiviral effects of baloxavir marboxil against influenza A virus infection in ferrets
por: Kitano, Mitsutaka, et al.
Publicado: (2020)